John J. Alam

Internal Medicine

130 Waverly St
Cambridge, MA 02139

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease.

Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease.

Journal: Journal of neuroinflammation

Published: August 18, 2025

Perspective: Minimally clinically important "symptomatic" benefit associated with disease modification resulting from anti-amyloid immunotherapy.

Perspective: Minimally clinically important "symptomatic" benefit associated with disease modification resulting from anti-amyloid immunotherapy.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: September 04, 2024

Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.

Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.

Journal: The journal of prevention of Alzheimer's disease

Published: May 06, 2024

Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.

Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.

Journal: Molecular neurodegeneration

Published: November 10, 2023

Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.

Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.

Journal: Molecular neurodegeneration

Published: September 15, 2023

Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.

Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.

Journal: Neurology

Published: February 06, 2023

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.

Journal: Nature communications

Published: March 29, 2022

Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration.

Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Published: August 14, 2021

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.

Journal: Alzheimer's research & therapy

Published: January 24, 2021

P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease.

P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease.

Journal: International journal of molecular sciences

Published: July 02, 2020

Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level.

Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level.

Journal: PloS one

Published: April 26, 2020

Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.

Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.

Journal: The journal of prevention of Alzheimer's disease

Published: May 08, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026